Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Astellas
Fierce Pharma
Astellas lifts forecast as Vyloy surge counters trial miss
Alongside a recorded loss pinned on Vyloy's pancreatic cancer setback, Astellas also terminated ASP4396, a phase 1 KRAS G12D program.
Angus Liu
Feb 5, 2026 11:00am
Fierce Pharma
Astellas CEO resists 'rescue BD' as Xtandi patent cliff nears
Jan 15, 2026 10:42am
Ocugen update charts course for rivalry with Apellis, Astellas
Jan 15, 2026 9:22am
Astellas turns down option to license Taysha gene therapy—again
Oct 17, 2025 10:50am
Japan biotech inks RNA research pact that includes mRNA compounds
Sep 19, 2025 10:49am
Astellas aims for CLDN18.2 gold with $1.34B licensing deal
May 29, 2025 7:30pm
